Prevalence and distribution of left ventricular diastolic dysfunction in treated patients with long-lasting

Ewa Świerblewska1, Jacek Wolf1, Katarzyna Kunicka1

  • 1a Department of Hypertension and Diabetology, Faculty of Medicine , Medical University of Gdańsk , Gdańsk , Poland.

Blood Pressure
|August 22, 2018
PubMed

Insights

Sub-clinical left ventricular diastolic dysfunction (LVDD) is common in treated hypertensive patients. Factors like female sex, age, obesity, diabetes, and higher blood pressure increase LVDD risk, while blood pressure treatment may reduce it.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Diastolic Function Assessment

Background:

  • Sub-clinical left ventricular diastolic dysfunction (LVDD) is a known cardiovascular risk factor.
  • Current guidelines do not classify LVDD as target organ damage in hypertension.
  • The relationship between hypertension and LVDD is complex due to co-existing risk factors.

Purpose of the Study:

  • To evaluate the prevalence and severity of diastolic dysfunction in treated hypertensive patients.
  • To identify predictors of LVDD in this population.
  • To assess the impact of hypertension management on LVDD.

Main Methods:

  • Retrospective analysis of 610 treated hypertensive patients from the CARE NORTH Study.
  • Exclusion of patients with overt cardiovascular disease, heart failure, or other specific conditions.
  • Staging of LVDD using comprehensive transthoracic echocardiography.

Main Results:

  • Nearly 50% of patients exhibited normal diastolic function.
  • Grade 1 LVDD was found in 24.4% and Grade 2 LVDD in 19.3% of patients.
  • Independent predictors of LVDD included female sex, older age, obesity, diabetes, higher SBP, and increased LVMI; blood-lowering therapy was protective.

Conclusions:

  • There is a high prevalence of diastolic dysfunction in treated hypertensive patients without overt cardiovascular disease.
  • LVDD should be considered in the risk assessment of hypertensive individuals.
  • Further research is needed to integrate LVDD assessment into hypertension guidelines.
Abstract

Related Concept Videos

Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.9K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
263
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
286
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
969